Immunotherapy combo shows promise in shrinking kidney tumors before surgery
NCT ID NCT05148546
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 31 times
Summary
This study tests whether giving immunotherapy before surgery can shrink tumors in people with a type of kidney cancer that is at high risk of coming back. About 69 adults with clear cell renal cell carcinoma will receive one of three drug combinations (nivolumab alone, nivolumab plus ipilimumab, or nivolumab plus relatlimab) for two cycles before their surgery. The main goal is to see how many patients have a significant reduction in their tumor after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Netherlands Cancer Institute
Amsterdam, North Holland, 1066CX, Netherlands
-
Royal Free London NHS Foundation Trust
London, NW3 2QG, United Kingdom
Conditions
Explore the condition pages connected to this study.